Conference Coverage

Survey reveals room for improvement in teen substance use screening


 

AT PAS 2023

Data highlight regional resource gaps

The current study is important because it highlights potential missed opportunities to screen adolescents for substance use, said Sarah Yale, MD, assistant professor of pediatrics at the Medical College of Wisconsin, Milwaukee, in an interview. Dr. Yale said that the disparities in screening by region are interesting and should serve as a focus for resource investment because the lack of specialists for referral and treatment options in these areas is likely a contributing factor.

However, lack of training also plays a role, said Dr. Yale, who was not involved in the study but served as a moderator of the presentation session at the meeting. Many pediatricians in practice have not been trained in substance use screening, and the fact that many of those who did try to screen were not using a standardized screening tool indicates a need for provider education, she said. The take-home message for clinicians is to find ways to include substance use screening in the care of their adolescent patients. Additionally, more research is needed to assess how best to integrate screening tools into visits, whether on paper, electronically, or verbally, and to include training on substance use screening during pediatric medical training.

The survey was conducted by the American Academy of Pediatrics Research Division. This year’s survey was supported by the Conrad N. Hilton Foundation. Dr. Camenga had no financial conflicts to disclose. Dr. Yale had no financial conflicts to disclose.

Pages

Recommended Reading

Lebrikizumab monotherapy for AD found safe, effective during induction
Federal Practitioner
Cutting social media to 1 hour a day boosts self-image in young adults
Federal Practitioner
Study finds quality of topical steroid withdrawal videos on YouTube subpar
Federal Practitioner
Substance abuse disorders may share a common genetic signature
Federal Practitioner
JAK inhibitor ivarmacitinib shows efficacy for atopic dermatitis in a pivotal trial
Federal Practitioner
FDA Advisory panels consider easing isotretinoin requirements
Federal Practitioner
FDA panels vote to modify isotretinoin iPLEDGE REMS
Federal Practitioner
Frustration over iPLEDGE evident at FDA meeting
Federal Practitioner
Is vaping a gateway to cigarettes for kids?
Federal Practitioner
Walnuts linked to improved attention, psychological maturity in teens
Federal Practitioner